Начало・Списък с акции・Merck & Co Inc.

Merck & Co Inc.

Затворен

СекторЗдравеопазване

130.3 -0.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

129.69

Максимум

132.76

Ключови измерители
By Trading Economics
Приходи	-7.2B -4.2B
Продажби	-114M 16B
P/E Средно за сектора	35.992 68.51
EPS	-1.28
Дивидентна доходност	2.52
Марж на печалбата	-26.053
Служители	73,000
EBITDA	-6.4B -2B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+6.13% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	2.52% 2.29%
Следващи печалби	29.10.2026 г.
Следваща дата на дивидент	7.10.2026 г.
Следваща дата на екс-дивидент	15.09.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	35B 307B
Предишно отваряне	130.71
Предишно затваряне	130.3

Настроения в новините

By Acuity

52%

48%

247 / 340 Класиране в Healthcare

Merck & Co Inc. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

10.08.2026 г., 19:36 ч. UTC

Social Media

News

Merck & Co Inc disclosed a $3.76 million stake in Evaxion Biotech, boosting shares higher amid positive sentiment and strong options trading ahead of earnings.

7.08.2026 г., 22:06 ч. UTC

Merck & Co Inc. shares were roughly flat in after-market hours. This stability aligns with broader positive sentiment on Wall Street amid easing interest rate concerns.

6.08.2026 г., 23:01 ч. UTC

Event

Merck & Co Inc shares are trading lower in after-market hours following the FDA's acceptance of a supplemental application for ENFLONSIA™.

5.08.2026 г., 19:43 ч. UTC

News

Social Media

Merck & Co. received Health Canada approval for Keytruda, yet shares are lower amid mixed market sentiment following disappointing ADP employment data.

4.08.2026 г., 23:26 ч. UTC

News

Merck & Co Inc reported a Q2 net loss of $1.3 billion. Shares are higher in after-market hours amid broader market gains from oil supply negotiations.

3.08.2026 г., 20:03 ч. UTC

News

Social Media

Merck & Co Inc shares are lower as the company prepares for Q2 earnings on August 4, despite reporting $16.29 billion in last quarter revenues.

31.07.2026 г., 23:16 ч. UTC

Merck & Co Inc shares are higher in after-market hours, maintaining a position near the upper end of their one-month range amid varied broader market performance.

30.07.2026 г., 20:09 ч. UTC

Merck & Co Inc shares are declining, with no specific news identified. Broader market volatility is influenced by mixed economic signals and jobless claims.

29.07.2026 г., 23:41 ч. UTC

Merck & Co Inc shares are lower in after-market hours, driven by weakness in the Pharmaceuticals sub-sector. The stock remains above its 20-day moving average.

28.07.2026 г., 23:01 ч. UTC

Merck & Co Inc shares are higher in after-market hours, maintaining stability above the 20-day moving average and near the upper end of their one-month range.

27.07.2026 г., 20:06 ч. UTC

Social Media

Merck & Co Inc shares are lower, testing the $132 level amid broader market declines and declining oil prices impacting Treasury yields ahead of the Fed meeting.

24.07.2026 г., 18:56 ч. UTC

News

Social Media

Merck & Co Inc. announced a strategy to enhance access to its HIV prevention drug Alimatravir across 129 countries, boosting shares during Friday's session.

22.07.2026 г., 19:46 ч. UTC

Social Media

Merck & Co Inc shares are higher, supported by strong contract performance valued at $1,000. The stock remains near its one-month high amid broader market challenges.

21.07.2026 г., 19:56 ч. UTC

News

Social Media

Merck & Co. Inc. shares are rising following positive Phase 3 trial results for its once-weekly oral HIV treatment regimen, islatravir and lenacapavir.

20.07.2026 г., 20:02 ч. UTC

Social Media

Merck & Co. shares are lower as the pharmaceutical sector faces pressure. The company plans to price Lipfendra at $10.50 per day.

Сравнение с други в отрасъла

Ценова промяна

Merck & Co Inc. Прогноза

Ценова цел

By TipRanks

6.13% нагоре

12-месечна прогноза

Среден 138.94 USD 6.13%

Висок 155 USD

Нисък 100 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Merck & Co Inc. през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

Купи

Задържане

Продай

Според 17 анализатори, дали борсови рейтинги на Merck & Co Inc. през последните 3 месеца.

Настроение

By Acuity

247 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.